Systematic therapies (for example, VEGF inhibitors, tyrosine kinase inhibitors and immune checkpoint inhibitors) are recommended as the first-line treatment for HCC with PVTT [6, 7]. Here, VEGFA is linked to hepatocellular carcinoma.